Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint of Overall Survival; Results to be Presented at Upcoming Medical Meeting
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Phase 3 KEYNOTE-604 trial investigating
KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy
met one of its dual primary endpoints of progression-free survival (PFS)
in the first-line treatment of patients with extensive stage small cell
lung cancer (ES-SCLC).
Media Contacts:
Pamela Eisele
(267) 305-3558
Kristen Drake
(908) 334-4688
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
